Recce Ltd has released a press release.
Recce to suspend anti-cancer program
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Operational Update and Quarterly Cash Flow
- Lead compound reduces illness in mice infected by E.coli
- Encouraging anti-viral activity for lead compound RECCE 327
- Pre-clinical toxicology and efficacy testing
- Dose Ranging in Mice - Repeated Success
Later from Recce Pharmaceuticals
- Microscopy Images of its Synthetic Antibiotic in Action Dest
- Appendix 4D and Interim Financial Statements
- Data from large animal study shows RECCE 327 well tolerated
- Operational Update
- Recce moves closer to clinical study application
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals